Lumos secures first FebriDx order under PHASE Scientific deal
Lumos Diagnostics Holdings Ltd (ASX:LDX) has received a US$767,800 FebriDx® purchase order from PHASE Scientific, marking the initial order drawn against a previously secured US$5.0 million prepayment milestone.
Product delivery is set to be fulfilled progressively between now and October 2026, with revenue recognised upon shipment. The order signals that the distribution agreement is beginning to convert into tangible revenue ahead of the US flu season.
When big ASX news breaks, our subscribers know first
What the order means for the PHASE Scientific agreement
The purchase order satisfies part of the Year 1 minimum order quantity commitment under the distribution agreement with PHASE Scientific. Rather than a standalone sale, it forms part of a structured, prepaid demand framework.
Key details from the announcement include:
-
The order will be credited against the US$5.0 million prepayment
-
The prepayment was received following the grant of a CLIA waiver for FebriDx® by the U.S. FDA on 27 March 2026
-
The remaining prepayment balance remains available to support subsequent purchase orders
This structure provides greater near-term revenue visibility, confirming a prepaid pipeline rather than a one-off transaction.
The record US$1.3 million FebriDx order placed by PHASE Scientific within five days of the March 2026 FDA clearance established an early commercial benchmark, and the current US$767,800 order continues that pattern of converting the prepayment structure into shipment-based revenue.
| Detail | Figure/Date | What It Means for Investors |
|---|---|---|
| Purchase order value | US$767,800 | First revenue drawdown under the agreement |
| Prepayment milestone | US$5.0M | Underpins future orders |
| FDA CLIA waiver | 27 March 2026 | Unlocked wider US market access |
| Delivery window | Through October 2026 | Revenue recognised on shipment |
Why FebriDx and CLIA waiver matter
FebriDx® is a rapid, point-of-care test for acute respiratory infection.
A CLIA waiver is a designation granted by the U.S. FDA. The CLIA waiver was granted in March 2026, prior to the receipt of the prepayment milestone that covers this order. The timing coincides with US healthcare providers preparing for the upcoming flu season.
The FDA CLIA waiver for FebriDx expanded Lumos’ addressable US market 15-fold to over US$1 billion, shifting the product from moderate-complexity laboratory settings to more than 300,000 point-of-care locations and unlocking roughly 80 million patient presentations annually.
Investment thesis and what comes next
This order strengthens the LDX case by demonstrating that FebriDx® commercialisation is progressing from regulatory approval toward repeat, prepaid revenue. It represents the initial order under the PHASE Scientific agreement, drawing on the structured commitment already in place.
CEO Commentary
“We are encouraged by the continued momentum as we advance the commercialisation of FebriDx®. This order comes at an important time as U.S. healthcare providers prepare for the upcoming flu season. We look forward to supporting the continued adoption of rapid, point-of-care acute respiratory infection testing across the U.S. market,” said Doug Ward, CEO and Managing Director of Lumos Diagnostics.
Looking ahead, the announcement points to the following next steps:
-
Progressive delivery of the current order through October 2026
-
Remaining prepayment balance available to fund subsequent orders
-
Continued FebriDx® adoption ahead of the US flu season
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already getting the edge on market-moving announcements. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.